Folic acid: friend or foe in cancer therapy

Abstract

Folic acid plays a crucial role in diverse biological processes, notably cell maturation and proliferation. Here, we performed a literature review using articles listed in electronic databases, such as PubMed, Scopus, MEDLINE, and Google Scholar. In this review article, we describe contradictory data regarding the role of folic acid in cancer development and progression. While some studies have confirmed its beneficial effects in diminishing the risk of various cancers, others have reported a potential carcinogenic effect. The current narrative review elucidates these conflicting data by highlighting the possible molecular mechanisms explaining each point of view. Further multicenter molecular and genetic studies, in addition to human randomized clinical trials, are necessary to provide a more comprehensive understanding of the relationship between folic acid and cancer.

Keywords

Breast cancer carcinogenic colorectal cancer folate folic acid lung cancer prostate cancer

Introduction

Folate is the natural form of vitamin B9. It is water-soluble and naturally found in plants and vegetables, such as dark leafy greens, citrus fruits, and meat products. Folate is also added to foods and sold as a supplement in the form of folic acid. In fact, this form is better absorbed than the folate form from food sources, 85% vs. 50%, respectively. This essential nutrient is a crucial part of many diverse biological processes. For example, it has an indispensable role in cell maturation and nucleotide synthesis through the methylation of uracil to thymine, which is essential for DNA synthesis and repair.^1,2 Moreover, folate metabolism is fundamental to both normal and cancer cell proliferation. Previous studies have suggested that folic acid has homocysteine lowering effects and is possibly beneficial for the prevention of cardiovascular disease (CVD) and stroke.^3,4 On the contrary, folic acid might also promote the progression of atherosclerosis because of its stimulatory effect on cell proliferation. After it was discovered that insufficient folate levels are linked to birth defects of the spine (spina bifida) and brain (anencephaly),^5–7 folic acid supplementation began being advised for women planning to conceive or those already pregnant as a proactive measure. This can help promote optimal fetal development and support a healthy pregnancy journey. Furthermore, not getting enough folic acid can lead to megaloblastic anemia.⁸

There are several conflicting studies regarding the relationship between folic acid and cancer risk.^9–12 Some reports have shed light on the protective effect of folic acid. Recent trials have suggested that taking folic acid, particularly during the preconception period and pregnancy, can prevent certain types of cancer, such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by reducing the risk of chromosomal abnormalities.¹³ In addition, other studies have shown that increased folate intake is significantly associated with a diminished risk of head and neck squamous cell carcinoma.¹⁴ In a case–control study by Li et al., a remarkable correlation was found between insufficient folate serum levels and an increased risk of cervical intraepithelial neoplasia (CIN) and cervical cancer.¹⁵ Other data from multiple studies showed that DNA methylation can serve as a biomarker for detecting colorectal cancer (CRC).¹⁶ Additionally, folic acid supplementation can increase DNA methylation levels in colonic tissues and leukocytes. A literature review reported that the risk of rectal cancer is higher in people who have Kirsten rat sarcoma (K-Ras)-mutated tumors with high folate consumption.¹⁷ Furthermore, research has indicated that high folate levels in heavy smokers can possibly exacerbate the cancer-causing effects of smoking.¹⁸

In this review, we delve into the contrasting data surrounding folic acid and its impacts on cancer risk. We describe the molecular mechanisms through which folic acid can induce cancer in certain individuals, while also highlighting the molecular pathways that may protect against cancer.

Folic acid and cancer protection

Folate plays a pivotal role in the prevention and management of various types of cancer. Several studies have demonstrated its influence on cancer risk and progression. Hwang et al. reported that elevated folate levels can impact S-adenosylmethionine (SAM) concentrations, thereby influencing cytochrome P450 2E1 (CYP2E1) expression levels and reducing the risk of oral cancer.¹⁹ Another study investigated the association between folate intake and reduced risks of esophageal adenocarcinoma and squamous cell carcinoma in high-risk populations.²⁰ Notably, these cancers are often associated with high alcohol and tobacco consumption, which can impair folate levels and thereby compromise genetic integrity.²¹ In lung cancer, several studies have suggested that higher folate intake, both from dietary sources and supplements, may have a protective effect.²² There is also emerging evidence that higher intake of nutrients related to one-carbon metabolism can lower the risk of renal cell cancer.²³ The intake of folic acid and multivitamin supplements may decrease the risk of leukemia, a common cancer among children under 15 years of age.²⁴ Maternal supplementation of folic acid has been linked to a reduced risk of ALL.²⁵ Williams and colleagues demonstrated in their research that folate has the potential to prevent sunlight-induced DNA damage and consequently reduce the risk of skin cancer.²⁶ Additionally, the photodegradation of folate by solar ultraviolet (UV) radiation may explain the better cancer prognosis observed in summer compared with winter months.²⁷ Observational studies have similarly indicated that adequate folate intake might reduce the risk of colon cancer²⁸ and breast cancer (BC),²⁹ particularly among individuals who consume alcohol. Furthermore, small clinical trials conducted over periods ranging from 3 months to 2 years have shown improvement in CRC biomarkers with folic acid supplementation exceeding 0.4 mg/day.³⁰ Interestingly, the Nurses’ Health Study found that higher folate intake could mitigate the increased risk of BC observed in women who consume more than one alcoholic drink per day.³¹ Additionally, various reports have suggested a synergistic interaction between folate intake and reduced colon cancer risk.³² A case–control study in Uruguay found an inverse relationship between folate intake and the risk of various cancer types.³³ Similarly, increased folate intake has been associated with a decreased risk of pancreatic cancer in women, although no significant effect was observed in men, possibly because of sex-related differences.^34,35 However, data from another study did not corroborate these associations.³⁶ Work by Butterworth and colleagues elucidated that inadequate levels of folic acid are related to an increased risk of cervical dysplasia, with folate supplementation leading to regression of the dysplastic lesions.³⁷ Mullin mentioned that folate had a protective effect against cancer initiation. However, after preneoplastic tumor formation, it may also help against cancer progression.³⁸ Finally, high folate consumption (≥300 μg per day) has been linked to a decreased risk of ovarian cancer, further underscoring the role of this nutrient in cancer prevention.³⁹

Protective mechanisms of folic acid in cancer

Folic acid plays a critical role in various biological processes, including DNA synthesis, repair, and methylation, making it essential for cell growth and division.⁴⁰ Folic acid has been studied for its potential protective effects against certain types of cancer, particularly when it is obtained through dietary sources or supplements. Below, we discuss some mechanisms through which folic acid may offer protection against cancer.

The role of folic acid role in DNA synthesis

Folates are crucial for the synthesis of purines and pyrimidines, which are necessary processes for accurate DNA replication. Adequate folate levels can reduce the likelihood of errors in the genetic code. This is critical for preventing DNA damage and mutations, which are key contributors to cancer development. With folic acid depletion, the conversion of dUMP cannot proceed, leading to its abnormal intracellular accumulation and misincorporation into DNA in place of thymine.⁴¹ Excessive uracil content can cause point mutations, single- and double-strand DNA breaks, chromosome breaks, and micronuclei formation.^42,43 Folate supplementation, along with vitamin B12, was shown to reverse the potential precursors of bronchial squamous cell carcinoma in the lungs, providing a biological basis for the protective effect of folate in reducing lung cancer risk.⁴⁴ Folate is also involved in DNA repair mechanisms. Damaged DNA is more likely to accumulate genetic mutations that can lead to uncontrolled cell growth, which is a hallmark of cancer.⁴⁵

Effects of folic acid on gene expression

Folates act as methyl group donors and are involved in DNA methylation, an essential epigenetic process that influences gene expression. Aberrant DNA methylation patterns, such as hypermethylation of tumor suppressor gene promoters or hypomethylation of oncogene promoters, are commonly observed in cancer cells.^46,47 DNA hypomethylation of oncogenes and hypermethylation of tumor suppressor genes are observed in pancreatic cancer.⁴⁸ Studies have shown that when patients with colorectal neoplasms are treated with high doses of folic acid, proper DNA methylation patterns can be restored.⁴⁹ Low folate levels, along with a methionine deficiency, can disrupt DNA methylation patterns, including methylation of a CpG island in the estrogen receptor (ER) gene. This has been suggested to potentially contribute to a higher incidence of ER-negative breast tumors.^50,51 Disrupted methylation is not limited to altered gene expression. Demethylation of centromeres can cause structural and functional aberrations within the chromosome, notably during mitosis, which lead to abnormal chromosome segregation and aneuploidy.⁵² Several studies have revealed a connection between folic acid deficiency and the incidence of aneuploidies involving chromosomes 17 and 21, which are commonly observed in BC and leukemia.^53,54 Similarly, chromosome 8⁵⁵ has been found to exhibit abnormal numbers in prostate cancer, skin cancer, BC, cholesteatoma, and leukemia. Notably, trisomy 8 is a recurrent chromosomal abnormality in AML, making it a recognized cytogenetic marker for AML.^56,57

Antioxidant properties of folic acid

Research has revealed that folic acid acts as a potent scavenger of free radicals and can effectively protect physiological components from oxidative stress. Despite its water-soluble nature, folic acid can also inhibit lipid peroxidation. The ability of folic acid to scavenge and repair thiyl radicals positions it as a potential antioxidant vitamin.⁵⁸ Sunlight is the major source of skin damage through direct DNA damage from the formation of pyrimidine dimers and other photoproducts.⁵⁹ Indirect damage can also occur via reactive oxygen species (ROS) and reactive carbonyl species (RCS) generation by photooxidation and photosensitization reactions.^60–62 Chronic DNA damage results in progressive losses of genomic integrity and end-stage skin damage in the form of skin cancer.⁶³ Most human papilloma virus (HPV) infections clear on their own without causing cervical abnormalities.⁶⁴ However, the persistence of genital HPV infections can lead to CIN and invasive cervical cancer, influenced by various infectious, behavioral, and lifestyle-related cofactors.^65,66 Lifestyle factors, such as smoking, exercise, and diet, can generate ROS, leading to oxidative stress and damage to biomolecules like lipids, proteins, and DNA. Oxidative stress is linked to several chronic diseases, including various cancers. Antioxidant deficiency can make an individual more susceptible to oxidative stress and thereby increase their cancer risk. Notably, exogenous antioxidant supplementation has been shown to reduce oxidative damage by scavenging ROS and decreasing the oxidation of cellular molecules.⁶⁷ Thus, dietary patterns can play a preventative role in various cancers, especially those of epithelial origin.⁶⁸

Role of folic acid in homocysteine regulation

Folate is involved in converting homocysteine into methionine.⁶⁹ Elevated homocysteine levels are associated with a higher risk of various diseases, including certain cancers.^70,71 In diabetes patients, plasma homocysteine levels can be elevated in insulin-resistant states (lowered by insulin).⁷² Therefore, adequate folate intake can help reduce homocysteine levels, potentially lowering the risk of pancreatic cancer.⁷³

Folic acid and collagen synthesis

Folate also participates in the synthesis of collagen, a structural protein in the skin. Healthy skin with proper collagen structure can provide better protection against UV radiation and may reduce the risk of skin cancer.²⁶ Additionally, cervical tissues benefit from proper collagen structure, making them more resistant to infections and cancerous changes.⁷⁴

Regulatory effects of folic acid on enzymes

S-adenosyl methionine is a naturally occurring compound that is produced as the body processes folate. One of its functions is regulating the expression and activity of CYP2E1, which converts ethanol into acetaldehyde and is primarily expressed in the liver. Increased folate levels can have an inhibitory effect on CYP2E1 expression.⁷⁵ Acetaldehyde is recognized as a potentially carcinogenic substance and is considered a contributing factor to oral cancer development.⁷⁶ Aldehyde dehydrogenase 1 (ALDH1), an enzyme responsible for metabolizing aldehydes like acetaldehyde, is regulated by three known response elements: nuclear factor Y (NF-Y), CCAAT/enhancer-binding protein-β (C/EBPβ), and retinoic acid receptor-α (RARα). Folate interacts with one of these response elements to enhance the expression of the ALDH1A1 and ALDH1L1 genes. This interaction may potentially help reduce cancer risk by lowering acetaldehyde levels and improving DNA stability.¹⁹

Overall, the relationship between folic acid and cancer is not entirely straightforward. In some cases, high-dose folic acid supplementation may have the opposite effect and potentially promote cancer, as discussed below. This is particularly relevant for individuals with pre-existing cancer or precancerous lesions. Additionally, the protective effects of folic acid may vary depending on the type of cancer. Figure 1 summarizes the currently known molecular mechanisms of the folic acid-mediated protective effects against cancer.

Figure 1.

Molecular mechanisms of the protective effect of folic acid against cancer. These mechanisms include its role in nucleotide synthesis, DNA methylation, homocysteine metabolism, DNA repair, and reduction of oxidative stress. ALDH1, Aldehyde Dehydrogenase 1; CYP2E1, Cytochrome P450 2E1.

Potential carcinogenic effect of folic acid

Despite the aforementioned studies, some reports have discussed an association of elevated folate intake with an increased risk of cancer progression. A literature review indicated that excessive intake of folate can increase the likelihood of precancerous cell growth.¹⁷ A randomized clinical trial (RCT) indicated a correlation between folic acid supplementation and an increased risk in pre-existing lesions and adenoma multiplicity.⁷⁷ There has been substantial interest in this topic. The interaction between folic acid and CRC is more complex. Several studies have revealed that individuals older than 50 years of age who take B vitamins, like B9 and B12, have a high risk of cancer, particularly CRC.^78–80 A nested case–control study performed by Van Guelpen et al. over a 4-year follow-up period showed that participants with elevated plasma folate levels had an approximately four-fold higher risk of CRC than those with lower levels.⁸¹ A large multicenter trial was conducted on a resected colorectal adenoma population who were randomly given either 1 mg of folic acid or a placebo over a 3- to 5-year follow-up period. Follow-up colonoscopy showed no protective impact of folic acid supplementation.⁷⁷ In fact, additional work found a notable risk in the multiplicity of recurrent adenomas with supplementation, as well as a marginally significant increase in “high-risk” adenomas.⁸² In controlled studies in a variety of colon cancer animal models, a setting in which neoplastic tumors are already present, intake of folic acid was no more protective. With established foci, additional microscopic foci and macroscopic tumors rapidly arose along with supplementation.^83,84 A potential link between lung cancer and folic acid intake has become a subject of interest. Stanisławska-Sachadyn and colleagues reported that folate levels above the median value (>17.5 nmol/L in the healthy controls) were associated with a high risk of lung cancer among smokers. It was also believed that smoking carcinogenicity was increased with the addition of folic acid intake in the heavy smoker population. Additionally, women with the solute carrier family 19 member 1N (SLC19A1) genotype and folic acid supplementation are at high risk of lung cancer.⁸⁵ Treatment with folic acid plus vitamin B12 was found to be related to increased cases of cancer and all-cause mortality in patients with ischemic heart disease in Norway, mainly driven by increased lung cancer incidence in participants.⁸⁶ The connection between folic acid and prostate cancer has also been a research focus. In a study conducted by Rycyna et al., increased blood folate levels were believed to play a role in prostate cancer development.⁸⁷ The results of a meta-analysis also supported this finding,⁸⁸ along with those of the Aspirin/Folate Polyp Prevention Study (AFPPS) trial, which followed patients with folic acid supplementation over 10 years.⁷⁷ Moreover, a study on cardiovascular patients who took folic acid to reduce homocysteine levels showed a high incidence of prostate cancer among men with a mean age of 60 years.⁸⁸ In a randomized trial, men who received folic acid as a preventative measure for colon polyp recurrence had increased prostate cancer diagnoses.⁸⁹ Likewise, Zhang et al. reported that routine intake of folate >400 µg/day could enhance the risk of BC.⁹⁰ A leading study observed a considerable positive association between total folate and supplemental folic acid intake amounts with postmenopausal BC.⁹¹ A trial was conducted among a population of pregnant women, with those who were randomly given the highest folic acid dose (5 mg/day) having a 70% greater risk of total cancer than the placebo group.⁹² In the 1940s, clinical investigators gave huge doses of folic acid to individuals with acute leukemia. Subsequently, the proliferation rate of the leukemic clone increased enormously,^93,94 corresponding to what Sidney Farber politely termed ‘‘the acceleration phenomenon’’.⁸² A cohort study was performed to explore the interrelationship between childhood cancer risk and high-dose folic acid consumption in mothers with epilepsy. The researchers found that prenatal exposure to a high-dose of folic acid could increase the risk of cancer by three-fold in the children of mothers with epilepsy who had filled the prescriptions for anti-seizure medication. However, the children of mothers with epilepsy who filled the prescriptions for anti-seizure medication, but not for high-dose folic acid, did not have an increased risk of cancer. In the folic acid-exposed groups, leukemia was the most common cancer type, followed by lymphoma and central nervous system tumors.⁹⁵

Molecular mechanisms of potential carcinogenic effects of folic acid

The roles of folate in nucleotide synthesis and as a cofactor in the rate-limiting step of DNA synthesis,⁹⁶ makes it a probable growth factor for neoplastic cells.⁸² Aggressively dividing cells, such as those present in solid tumors, have high consumption rates of particular vitamins. As a result, there is overexpression of the receptors responsible for the uptake of those vitamins.⁹⁷ Additionally, many cancer cells can upregulate the expression of membrane receptors that mediate folate uptake, as well as the expression of certain critical folate-dependent enzymes that are necessary for DNA synthesis.^98,99 There are two folate receptors, folate receptor α (FR-α) and FR-β, which are both expressed in malignant tissues of epithelial and non-epithelial origin.⁹⁷ Furthermore, they have been detected in ovarian carcinoma (>90%), lung cancer (50%), BC (25%), endometrial cancer, renal cancer (50%), CRC (including Caco-2 cells), and cancers of myeloid hematopoietic cells, the brain (66%), and placental cells.⁹⁷ FR expression levels in tumors have also been directly associated with the tumor stage.⁹⁷

CRC

One potential mechanism behind the folic acid-mediated promotion of CRC growth is its ability to provide nucleotide precursors to rapidly replicating neoplastic cells. These precursors can facilitate accelerated cell proliferation and growth. Because nucleotides are the fundamental building blocks of DNA, rapidly dividing cancer cells require a substantial supply of nucleotides for DNA replication. Folic acid can stimulate nucleotide synthesis, giving cancer cells growth and proliferation advantages.¹⁰⁰ Additionally, folic acid can possibly promote CRC through de novo methylation of promoter CpG islands of tumor suppressor genes. This process can lead to gene inactivation, which contributes to tumor progression. The addition of methyl groups to DNA at CpG islands is an epigenetic modification that can silence gene expression. Tumor suppressor genes act as safeguards against uncontrolled cell growth and proliferation.¹⁰¹ When these genes are silenced through DNA methylation, cancer cells can grow and multiply without restraint.⁹ The ability of folic acid to provide methyl groups can enhance the DNA methylation process, ultimately leading to the suppression of tumor suppressor gene expression and increased CRC growth and progression. E-cadherin, a transmembrane glycoprotein and member of the cadherin family of cell adhesion molecules, mediates cell–cell adhesion via calcium-dependent interactions. E-cadherin may function as a tumor suppressor gene in tumor invasion and metastasis.¹⁰² Pellis et al. concluded that the presence of high folic acid levels (100 ng/mL) are associated with a significant decline in E-cadherin expression levels in colon cancer cells in vitro.¹⁰³

Lung cancer

Polymorphisms in folate metabolic pathway genes have been demonstrated to alter serum folate levels. The 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme can affect folate distribution for DNA synthesis and methylation. Individuals with the MTHFR 667 C->T genotype have been found to have an increased risk of lung cancer. People with at least one variant allele for MTHRF 667 and serine hydroxymethyltransferase (SHMT) also displayed a higher lung cancer risk compared with wild-type carriers for both genes.^104,105 Another study showed that the SLC19A1 c.80>A genotype was associated with lung cancer risk, while the SLC19A1 c.80AA genotype correlated with a higher risk in women and a lower risk in men, contrary to the GG genotype.⁸⁵

Prostate cancer

Folate has an essential role in the synthesis of nucleotides that are required for neoplastic cell proliferation. Folate receptor expression levels are also increased in several cancer types.⁹⁸ PSMA, a type II membrane protein with glutamate carboxypeptidase activity, is overexpressed in prostate cancer when folate hydrolase is active.^106,107 Elevated PSMA expression levels are correlated with higher tumor grade, higher Gleason score, and disease recurrence.^108,109 Folate also has a key role in DNA methylation.^110,111 Changes in methylation patterns involving global DNA hypomethylation¹¹² and gene-specific hypomethylation¹¹³ appear to be important molecular events in prostate cancer. One study showed that the MTHFR A1298C genotype is associated with a two-fold higher risk of low-grade prostate cancer. A positive correlation was observed between serum folate levels and prostate cancer incidence with a dose-response relationship among men of predominantly African origin. For the MTHFR A1298C, MTHFR C677T, MTRR A66G, and MTR A2756G polymorphisms, men who had both high folate concentrations and a variant genotype showed a greater likelihood for total prostate cancer incidence compared with men with low folate concentrations and wild-type genotypes.¹¹⁴

BC

Folic acid can contribute to epigenetic changes in gene-regulatory mechanisms, which may lead to gene silencing and enhanced BC development.⁹⁷ It can also promote the growth of tumors that express FR-α, which is approximately 25% of BC cases.⁹¹ A cohort study conducted on triple negative breast cancer (TNBC) patients detected FR-α overexpression, which may confer a growth advantage to epithelial tumors by improving folate uptake. Therefore, these TNBC patients may benefit from targeted anti-FRα therapy.¹¹⁵ Very high folic acid intake can possibly enhance the growth of an existing breast neoplasm or cancer.⁸⁰ Because of this, folic acid deprivation with anti-folate chemotherapy, such as 5-fluorouracil, methotrexate, or other drugs that interfere with thymidylate uptake and ultimately DNA synthesis, is considered a sufficient treatment approach for BC patients.¹¹⁶ Figure 2 summarizes the molecular mechanisms of the potential carcinogenic effects of folic acid.

Figure 2.

Molecular mechanisms of the carcinogenic potential of folic acid. CpG, Cytosine-phosphate-Guanine; E-Cadherin, Epithelial Cadherin; FR-α, folate receptor-alpha; FR-β, folate receptor-beta; MTHFR, methyltetrahydrofolate reductase; SHMT, serine hydroxymethyltransferase; SLC19A1, Solute Carrier Family 19 Member 1.

The impact of folate on cancer risk is influenced by several factors. Timing plays a critical role, as folate appears to be more protective during early developmental stages, such as fetal development or periods of rapid cell division, like pregnancy.^13,24,25 However, its effects may differ during adulthood, particularly among individuals with pre-existing cancer or precancerous lesions.³⁴ The specific dosage of folate is another key factor to consider. While moderate dietary intake of folate is generally considered beneficial, high-dose folic acid supplementation can yield contrasting effects. Excessive supplementation can lead to unexpected consequences, potentially promoting cancer growth, especially among individuals with specific genetic mutations.^117,118 Furthermore, individual variability is a significant factor. Responses to folate can vary based on genetic factors, including mutations in specific genes that are related to folate metabolism.¹¹⁹

Mandatory fortification of folic acid

Food fortification is the insertion of essential micronutrients that are lacking in a population’s diet into commonly consumed foods during processing.¹²⁰ This process was a milestone that can help reduce micronutrient deficiencies in different aspects.¹²¹ Undoubtedly, these deficiencies can affect an individual’s survival, as well as their mental and physical development, which in turn can influence the economies of countries.^122,123 Indeed, a large portion of the population must be treated to have a significant positive effect on public health.¹²⁴ Given these issues, mandatory fortification programs have been implemented in many countries to maximize their effects and reduce the high costs associated with prevention programs, such as education campaigns and other intervention methods that require behavioral changes.¹²⁵

Folic acid is one critical micronutrient that can be delivered by fortification and is considered one of the most significant public health interventions worldwide.¹²⁶ Folic acid intervention by flour fortification (wheat or maize flour fortification) has been done in over 80 countries.¹¹⁴ Periconceptional supplementation to reduce a childbearing age woman’s susceptibility to having an infant with a neural tube defect (NTD)¹²⁷ can also be performed. The association of NTDs and folate has been one of the most successful public health initiatives in the past 50 to 75 years,¹²⁸ with a recommended folic acid dose of 400 μg per day to prevent NTDs.¹²⁹ Surveys in the United States have indicated a decline of 19% to 32% in NTD prevalence since the initiation of folic acid fortification in 1998.^130–133 Additionally, Canada, South Africa, Costa Rica, Chile, Argentina, and Brazil have shown declines in NTDs (19% to 55%) since fortification began.^134–143 Some unintended benefits have also been observed with folic acid fortification. These include elevated hemoglobin concentrations and a lower CVD risk, mainly by a reduction of total homocysteine (tHcy), an independent risk factor of CVD.¹⁴⁴ Enhanced cognitive function is also an observed benefit.¹⁴⁵ A collective analysis of six RCTs mentioned that a depression score reduction occurred with folic acid supplementation. Even people who are diagnosed with depression or at risk of depression must ensure they have the appropriate amount of folic acid.¹⁴⁴

There are some concerns regarding folic acid fortification, despite the reduced incidence of NTDs discussed above.¹²⁷ It can potentially lead to massive consumption levels, which might result in adverse effects. It may be necessary to continue monitoring fortification interventions to quickly identify any emerging concern and investigate it further.¹⁴⁶ These potential adverse effects include the masking of vitamin B12 deficiency anemia, which can progress to neuropathies. This would delay the diagnosis of the anemia,^147,148 although a recent study has disproved this effect.¹⁴⁹ In addition, other work revealed that unmetabolized folic acid is present in circulation after consuming over 200 μg of folic acid.¹⁵⁰ This could be associated with cognitive impairment among seniors.¹⁵¹

A potential, but controversial, influence of folic acid fortification is cancer development. Many articles have been published that argue how folic acid can affect cancer progression, oscillating between its ability to reduce cancer progression, increase susceptibility to cancer development, or no association at all. American and Canadian ecologic studies have demonstrated a decline in childhood cancer incidence after folic acid fortification was initiated, with an estimated dose below 0.4 mg per day.^152–154 Other papers have indicated a minimized risk of childhood central nervous system tumors¹⁵⁵ and ALL^25,156,157 according to self-reported folic acid consumption at doses nearly 0.4 mg per day, with no certain consumption of more than 0.8 mg. There was no detected change in the pre-fortification versus post fortification duration for ALL, brain cancers, embryonal cancers, or hepatoblastoma among the 0- to 4-year or 5- to 9-year age groups.¹⁵³ An approximately 30% decline of Wilms’ tumor risk was observed after the intervention started, as well as a 60% decline in neuroblastoma.¹⁵² Additional studies are needed in the United States during the post-folic acid grain fortification era, but preliminary analysis has suggested that folic acid grain fortification did not affect the risk of pancreatic cancer.³⁵

Other evidence has shown that high folic acid intake has increased certain health risks in specific populations, including men with prostate cancer.^158,159 Excessive circulating folate was observed following the fortification approach, which covered 1% to 4% of the United States population.^158,160 Furthermore, dietary supplement users account for more than 10% of the population. This will result in folic acid consumption over the upper tolerable limit.^159,161 Another study perhaps supports the concerns that folic acid fortification has led to an increased risk of lung cancer in cigarette smokers along with high folic acid levels.⁸⁵

Certain public health crises have emerged, in part by folic grain fortification and overall supplemental use of folic acid.^162–164 A probable cancer-promoting impact of significantly high folate and folic acid intake and blood levels have been suggested in North America. This has also been corroborated by animal studies and clinical trial outcomes.^77,83 Individuals within the nutrition community have conveyed worries that elevated folic acid intake, either from fortification or supplements, may accidentally increase the cancer risk among people in the United States.^80,82 The United States implemented mandatory fortification of cereal grains with folic acid in 1998 during pregnancy. Since then, the BC risk increased with consumption of these highly fortified cereals.⁹¹

In response to some concerns, mandatory folic acid fortification is not established in Europe. Voluntary folic acid fortification strategies are applied in the United Kingdom, while other regions have no fortification strategy.¹⁴⁴ One article showed that folic acid fortification is retained in the current version of the Lives Saved Tool (LiST). Although fortification programs are being introduced in most low and middle-income countries, the impacts of these programs have been restricted either by low levels of fortification in industrialized food, low consumption of fortified food, or both.¹⁶⁵

Folic acid receptors and cancer risk: future prospectives

Many types of human cancer, such as BC, ovarian cancer, endometrial cancer, lung cancer, CRC, and cerebral tumors, have shown increased FR expression levels compared with healthy tissues.^166,167 FR can be a target to improve cancer therapy outcomes. Through nanoformulations, the effectiveness and potency of anti-cancer drugs can be enhanced by targeting FR by using folic acid or other chemically-related agents that have a high affinity for FRs. Monoclonal antibodies against FRs are also used.¹⁶⁸ FR-α expression has been observed in the choroid plexus. Thus, FR-targeted formulations could be a good approach for improving the passage of anti-cancer agents to the central nervous system.¹⁶⁹ The present review recommends novel future pharmacogenomic studies involving the alteration of FR expression in different types of cancer to potentially help improve the efficacy of anti-cancer drugs.

Conclusion

The current review describes study results that suggest opposing roles for folic acid in different types of cancer. Further pharmacogenomic studies and promising multicenter clinical trials are necessary to provide a more comprehensive understanding of this conflicting issue. These will provide additional evidence to help determine if folic acid can be used as a prophylactic supplement to reduce the risk of cancer or as an adjuvant to current anti-cancer protocols. If the results suggest that folic acid is carcinogenic, then high intake should be avoided, especially for those with an increased cancer risk.

Footnotes

Author contributions

All authors contributed to the conceptualization of the current review article. RHT finalized the editing of the manuscript. All authors contributed equally to data collection and editing/revising the manuscript and agree to be accountable for all aspects of the work.

Data availability statement

The data from the current study are accessible from the corresponding authors upon reasonable request.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Romany H. Thabet

References

Duthie

Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999; 55: 578–592.

Reidy

JA.

Folate and deoxyuridine sensitive chromatid breakage may result from DNA repair during G2. Mutat Res 1987; 192: 217–219.

Rimm

Willett

, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359–364.

Forman

Rimm

Stampfer

, et al. Folate intake and the risk of incident hypertension among US women. JAMA 2005; 293: 320–329.

Smithells

Sheppard

Schorah

CJ.

Vitamin dificiencies and neural tube defects. Arch Dis Child 1976; 51: 944–950.

Czeizel

Dudás

Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–1835.

MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131–137.

Green

Datta Mitra

Megaloblastic Anemias: Nutritional and Other Causes. Med Clin North Am 2017; 101: 297–317.

Kim

YI.

Folate: a magic bullet or a double edged sword for colorectal cancer prevention?

Gut 2006; 55: 1387–1389.

10.

Mason

Kim

SJ.

Revisiting the goldilocks phenomenon: folate and colorectal cancer risk. Am J Gastroenterol 2010; 105: 1914–1916.

11.

Glynn

Albanes

Folate and cancer: a review of the literature. Nutr Cancer 1994; 22: 101–119.

12.

Miller

Ulrich

CM.

Folic acid and cancer—where are we today?

Lancet 2013; 381: 974–976.

13.

Cantarella

Ragusa

Giammanco

, et al. Folate deficiency as predisposing factor for childhood leukaemia: a review of the literature. Genes Nutr 2017; 12: 14.

14.

Fan

Zhang

, et al. Association between folate intake and risk of head and neck squamous cell carcinoma: An overall and dose-response PRISMA meta-analysis. Medicine (Baltimore) 2017; 96: e8182.

15.

Yang

Wang

, et al. Folic Acid Intake and Folate Status and Risk of Cervical Cancer: A Systematic Review and Meta-Analysis from 20 Independent Case-Control Studies and 4 RCTs. Curr Dev Nutr 2020; 4: 330.

16.

Gutierrez

Demond

Brebi

, et al. Novel Methylation Biomarkers for Colorectal Cancer Prognosis. Biomolecules 2021; 11: 1722.

17.

Kherbek

Daoud

Soueycatt

, et al. The relationship between folic acid and colorectal cancer; a literature review. Ann Med Surg (Lond) 2022; 80: 104170.

18.

Shulpekova

Nechaev

Kardasheva

, et al. The Concept of Folic Acid in Health and Disease. Molecules 2021; 26: 3731.

19.

Hwang

Lian

Zavras

AI.

Alcohol intake and folate antagonism via CYP2E1 and ALDH1: effects on oral carcinogenesis. Med Hypotheses 2012; 78: 197–202.

20.

Ibiebele

Hughes

Pandeya

, Study of Digestive Health; Australian Cancer Studyet al. High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr 2011; 141: 274–283.

21.

Galeone

Edefonti

Parpinel

, et al. Folate intake and the risk of oral cavity and pharyngeal cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2015; 136: 904–914.

22.

Dai

Yang

Chu

, et al. Association between folate intake, serum folate levels and the risk of lung cancer: a systematic review and meta-analysis. Chin Med J (Engl) 2013; 126: 1957–1964.

23.

Cho

Giovannucci

Joh

HK.

Nutrients related to one-carbon metabolism and risk of renal cell cancer. Cancer Causes Control 2013; 24: 373–382.

24.

Ward

DeSantis

Robbins

, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83–103.

25.

Thompson

Gerald

Willoughby

, et al. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. Lancet 2001; 358: 1935–1940.

26.

Williams

Jacobson

Kim

, et al. Folate in skin cancer prevention. Subcell Biochem 2012; 56: 181–197.

27.

Steindal

Porojnicu

Moan

Is the seasonal variation in cancer prognosis caused by sun-induced folate degradation?

Med Hypotheses 2007; 69: 182–185.

28.

Giovannucci

Stampfer

Colditz

, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med 1998; 129: 517–524.

29.

Chen

, et al. Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis. Br J Cancer 2014; 110: 2327–2338.

30.

Kim

YI.

Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 2007; 51: 267–292.

31.

Zhang

Hunter

Hankinson

, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281: 1632–1637.

32.

Arab

Nutritional status of folate and colon cancer risk: evidence from NHANES I epidemiologic follow-up study. Ann Epidemiol 2001; 11: 65–72.

33.

Aune

Deneo-Pellegrini

Ronco

, et al. Dietary folate intake and the risk of 11 types of cancer: a case-control study in Uruguay. Ann Oncol 2011; 22: 444–451.

34.

Skinner

Michaud

Giovannucci

, et al. A prospective study of folate intake and the risk of pancreatic cancer in men and women. Am J Epidemiol 2004; 160: 248–258.

35.

Oaks

Dodd

Meinhold

, et al. Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr 2010; 91: 449–455.

36.

Keszei

Verhage

Heinen

, et al. Dietary folate and folate vitamers and the risk of pancreatic cancer in the Netherlands cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1785–1791.

37.

Butterworth

Jr Hatch

Gore

, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 1982; 35: 73–82.

38.

Mullin

GE.

Folate: is too much of a good thing harmful?

Nutr Clin Pract 2011; 26: 84–87.

39.

Kotsopoulos

Hecht

Marotti

, et al. Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors. Int J Cancer 2010; 126: 2191–2198.

40.

Crider

Yang

Berry

, et al. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr 2012; 3: 21–38.

41.

Eto

Krumdieck

CL.

Role of vitamin B12 and folate deficiencies in carcinogenesis. Essential nutrients in carcinogenesis. New York: Plenum Press. 1986; 313–330.

42.

Blount

Mack

Wehr

, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A 1997; 94: 3290–3295.

43.

Blount

Ames

BN.

DNA damage in folate deficiency. Baillieres Clin Haematol 1995; 8: 461–478.

44.

Shen

Wei

Pillow

, et al. Dietary Folate Intake and Lung Cancer Risk in Former Smokers: A Case-Control Analysis1. Cancer Epidemiol Biomarkers Prev 2003; 12: 980–986.

45.

Ulrich

Reed

Nijhout

HF.

Modeling folate, one carbon metabolism and DNA methylation. Nutr Rev 2008; 66: S27–S30.

46.

Taberlay

Jones

PA.

DNA methylation and cancer. Epigenetics and Disease Springer Basel. 2011: 1–23.

47.

Gaudet

Hodgson

Eden

, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 489–492.

48.

Larsson

Håkansson

Giovannucci

, et al. Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst 2006; 98: 407–413.

49.

Jaszewski

Khan

Sarkar

, et al. Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines. Am J Physiol 1999; 277: C1142–C1148.

50.

Lapidus

Nass

Butash

, et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998; 58: 2515–2519.

51.

Ferguson

Lapidus

Baylin

, et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995; 55: 2279–2283.

52.

Zingg

Jones

PA.

Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997; 18: 869–882.

53.

Wang

Thomas

Xue

, et al. Folate deficiency induces aneuploidy in human lymphocytes in vitro—evidence using cytokinesis-blocked cells and probes specific for chromosomes 17 and 21. Mutat Res 2004; 551: 167–180.

54.

Beetstra

Thomas

Salisbury

, et al. Folic acid deficiency increases chromosomal instability, chromosome 21 aneuploidy and sensitivity to radiationinduced micronuclei. Mutat Res 2005; 578: 317–326.

55.

Fenech

, et al. Folate deficiency in human peripheral blood lymphocytes induces chromosome 8 aneuploidy but this effect is not modified by riboflavin. Environ Mol Mutagen 2010; 51: 15–22.

56.

Maserati

Aprili

Vinante

, et al. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15–20% of cases. Genes Chromosomes Cancer 2002; 33: 93–97.

57.

Paulsson

Johansson

Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol (Paris) 2007; 55: 37–48.

58.

Joshi

Adhikari

Patro

, et al. Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity. Free Radic Biol Med 2001; 30: 1390–1399.

59.

Ullrich

SE.

Photoimmune suppression and photocarcinogenesis. Front Biosci 2002; 7: 684–703.

60.

Wondrak

Cervantes-Laurean

Roberts

, et al. Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress. Biochem Pharmacol 2002; 63: 361–373.

61.

Wondrak

Roberts

Jacobson

, et al. Photosensitized growth inhibition of cultured human skin cells: Mechanism and suppression of oxidative stress from solar irradiation of glycated proteins. J Invest Dermatol 2002b; 119: 489–498.

62.

Wondrak

Roberts

Cervantes-Laurean

, et al. Proteins of the extracellular matrix are sensitizers of photo-oxidative stress in human skin cells. J Invest Dermatol 2003; 121: 578–586.

63.

Jeffes

3rd Tang

EH.

Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1: 167–179.

64.

Wideroff

Potischman

Glass

, et al. A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix. Nutr Cancer 1998; 30: 130–136.

65.

Plummer

Herrero

Franceschi

, IARC Multi-centre Cervical Cancer Study Groupet al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes Control 2003; 14: 805–814.

66.

Juneja

Sehgal

Mitra

, et al. A survey on risk factors associated with cervical cancer. Indian J Cancer 2003; 40: 15–22.

67.

Rao

LG.

Carotenoids and human health. Pharmacol Res 2007; 55: 207–216.

68.

La Vecchia

Decarli

Fasoli

, et al. Dietary vitamin A and the risk of intraepithelial and invasive cervical neoplasia. Gynecol Oncol 1988; 30: 187–195.

69.

Forges

Monnier-Barbarino

Alberto

, et al. Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update 2007; 13: 225–238.

70.

Sun

Haven

, et al. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta 2002; 321: 55–62.

71.

JT.

Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 2002; 322: 21–28.

72.

Godsland

Rosankiewicz

Proudler

, et al. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 2001; 86: 719–723.

73.

Hemati

Moghadami-Tabrizi

Davari-Tanha

, et al. High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome. Iran J Reprod Med 2011; 9: 223–228.

74.

Dong

Bai

, et al. Interactions between microbiota and cervical epithelial, immune, and mucus barrier. Front Cell Infect Microbiol 2023; 13: 1124591.

75.

Caro

Cederbaum

AI.

Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-Lmethionine. Biochem Pharmacol 2005; 69: 1081–1093.

76.

Seitz

Meier

The role of acetaldehyde in upper digestive tract cancer in alcoholics. Transl Res 2007; 149: 293–297.

77.

Cole

Baron

Sandler

, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297: 2351–2359.

78.

Oliai Araghi

Kiefte-de Jong

Van Dijk

, et al. Folic acid and vitamin B12 supplementation and the risk of cancer: Long-term follow-up of the B vitamins for the prevention of osteoporotic fractures (B-PROOF) trial. Cancer Epidemiol Biomarkers Prev 2019; 28: 275–282.

79.

Kim

Masih

Kim

YI.

Folate DNA methylation and colorectal cancer. In: Ho

Domann

, editors. Nutrition and epige- netics. Boca Raton: Taylor & Francis Group CRC Press; 2014; 113–161.

80.

Kim

YI.

Will mandatory folic acid fortification prevent or promote cancer?

Am J Clin Nutr 2004; 80: 1123–1128.

81.

Moazzen

Dolatkhah

Tabrizi

, et al. Folic acid intake and folate status and colorectal cancer risk: A systematic review and meta-analysis. Clin Nutr 2018; 37: 1926–1934.

82.

Mason

Dickstein

Jacques

, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 2007; 16: 1325–1329.

83.

Song

Medline

Mason

JB.

Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 2000; 60: 5434–5440.

84.

Song

Sohn

Medline

Chemopreventive effects of dietary folate on intestinal polyps in Apc+/Msh2/mice. Cancer Res 2000; 60: 3191–3199.

85.

Stanisławska-Sachadyn

Borzyszkowska

Krzemiński

, et al. Folate/homocysteine metabolism and lung cancer risk among smokers. PLoS ONE 2019; 14: e0214462.

86.

Ebbing

Bønaa

Nygård

, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302: 2119–2126.

87.

Rycyna

Bacich

O'Keefe

DS.

Opposing roles of folate in prostate cancer. Urology 2013; 82: 1197–1203.

88.

Wien

Pike

Wisløff

, et al. Cancer risk with folic acid supplements: a systematic review and metaanalysis. BMJ Open 2012; 2: e000653.

89.

Figueiredo

Grau

Haile

, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101: 432–435.

90.

Zhang

Shi

Gao

, et al. Folate intake and the risk of breast cancer: a dose-response meta-analysis of prospective studies. PLoS One 2014; 9: e100044.

91.

Stolzenberg-Solomon

Chang

Leitzmann

, et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr 2006; 83: 895–904.

92.

Lehman

NL.

Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 2002; 11: 1775–1787.

93.

Farber

Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 1949; 4: 160–167.

94.

Heinle

Welch

AD.

Experiments with pteroylglutamicacid and pteroylglutamic acid deficiency in human leukemia [abstract]. J Clin Invest 1948; 27: 539.

95.

Vegrim

Dreier

Alvestad

, et al. Cancer risk in children of mothers with epilepsy and high-dose folic acid use during pregnancy. JAMA Neurol 2022; 79: 1130–1138.

96.

Wagner

Biochemical role of folate in cellular metabolism. In: Bailey

, editor. Folate in health and disease. New York: Marcel Dekker; 1995. p. 23–42.

97.

Russell-Jones

McTavish

McEwan

, et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 2004; 98: 1625–1633.

98.

Kelemen

LE.

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

Int J Cancer 2006; 119: 243–250.

99.

Voeller

Rahman

Zajac-Kaye

Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells. Cell Cycle 2004; 3: 1005–1007.

100.

Kim

YI.

Folate and carcinogenesis: Evidence, mechanisms, and implications. J Nutr Biochem 1999; 10: 66–88.

101.

Jones

Baylin

SB.

The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–428.

102.

Tisman

Garcia

Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. J Med Case Rep 2011; 5: 413.

103.

Pellis

Dommels

Venema

, et al. High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr 2008; 99: 703–708.

104.

Siemianowicz

Gminski

Garczorz

, et al. Methylenetetra- hydrofolate reductase gene C677T and A1298C polymorphism in patients with small cell and non-small cell lung cancer. Oncol Rep 2003; 10: 1341–1344.

105.

Boccia

Boffetta

Brennan

, et al. Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett 2009; 273: 55–61.

106.

Yao

Bacich

DJ.

Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 2006; 66: 867–875.

107.

Lapidus

Tiffany

Isaacs

, et al. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000; 45: 350–354.

108.

Kawakami

Nakayama

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57: 2321–2324.

109.

Ross

Sheehan

Fisher

, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357–6362.

110.

Choi

Mason

JB.

Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002; 132: 2413S–2418S.

111.

Kim

YI.

Role of folate in colon cancer development and progression. J Nutr 2003; 133: 3731S–3739S.

112.

Brothman

Swanson

Maxwell

, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005; 156: 31–36.

113.

Wang

Williamson

Bott

, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007; 26: 6560–6565.

114.

Jackson

Tulloch-Reid

McFarlane-Anderson

, et al. Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr 2013; 8: 199–207.

115.

Norton

Youssef

Hillman

, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer 2020; 6: 4.

116.

Sohn

Croxford

Yates

, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134–144.

117.

Sauer

Mason

Choi

SW.

Too much folate: a risk factor for cancer and cardiovascular disease?

Curr Opin Clin Nutr Metab Care 2009; 12: 30–36.

118.

Matthews

Daubner

SC.

Modulation of methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues. Adv Enzyme Regul 1982; 20: 123–131.

119.

Hiraoka

Kagawa

Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57: 142–149.

120.

World Health Organization Food and Agriculture O, L and Allen B. de Benoist. O. Dary, R. Hurrell (Eds.), Guidelines on Food Fortification with Micronutrients. World Health Organization, World Health Organization, Geneva (2006).

121.

Keats

Neufeld

Garrett

, et al. Bhutta Improved micronutrient status and health outcomes in low- and middle-income countries following large-scale fortification: evidence from a systematic review and meta-analysis Am. J Clin Nutr 2019; 109: 1696–1708.

122.

Horton

Gelband

Jamison

, et al. Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness. Plos ONE 2017; 12: e0182951.

123.

Horton

and Alderman. (2009). Hunger and malnutrition. In Lomborg

(Ed.), Global Crises, Global Solutions: Costs and Benefits. (pp. 305–354). Cambridge: Cambridge University Press.

124.

Rohner

Wirth

Zeng

, et al. Global coverage of mandatory large-scale food fortification programs: A systematic review and meta-analysis. Adv Nutr 2023; 14: 1197–1210.

125.

Flour Fortification Initiative, authors. Report of the workshop of wheat flour fortification. Cuernavaca, Mexico. [(accessed on August 21, 2010)].

126.

Centeno Tablante

Pachón

Guetterman

, et al. Fortification of wheat and maize flour with folic acid for population health outcomes. Cochrane Database Syst Rev 2019; 7: CD012150.

127.

Williams

Mai

Mulinare

, et al. Updated estimates of neural tube defects prevented by mandatory folic Acid fortification. Mmwr Morb Mortal Wkly Rep 2015; 64: 1–5.

128.

Jin

Folic acid supplementation for prevention of neural tube defects. JAMA 2017; 317: 222.

129.

Berry

Mulinare

Hamner

HC.

Folic acid fortification: neural tube defect risk reduction—a global perspective. In: Bailey

L.B.

, editor. Folate in Health and Disease. 2nd. CRC Press; Boca Raton, FL, USA: 2010.

130.

Williams

Mai

Edmonds

, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002; 66: 33–39.

131.

Honein

Paulozzi

Mathews

, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285: 2981–2986.

132.

Mathews

TJ.

Trends in spina bifida and anencephalus in the United States, 1991–2005. [(accessed on May 2, 2008)].

133.

Boulet

Yang

Mai

, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 2008; 82: 527–532.

134.

Canada Gazette Food and Drugs Regulations, authors. SOR/96-527. [(accessed on September 27, 2008)].

135.

Chen

Rivera

MA.

The Costa Rican experience: reduction of neural tube defects following food fortification programs. Nutr Rev 2004; 62: S40–S43.

136.

Hertrampf

Cortes

Folic acid fortification of wheat flour: Chile. Nutr Rev 2004; 62: S44–S48.

137.

Sayed

Bourne

Pattinson

, et al. Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. Birth Defects Res A Clin Mol Teratol 2008; 82: 211–216.

138.

De Wals

Rusen

Lee

, et al. Trend in prevalence of neural tube defects in Quebec. Birth Defects Res A Clin Mol Teratol 2003; 67: 919–923.

139.

Ray

Meier

Vermeulen

, et al. Association of neural tube defects and folic acid food fortification in Canada. Lancet 2002; 360: 2047–2048.

140.

Persad

Van den Hof

Dube

, et al. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. Can Med Assoc J 2002; 167: 241–245.

141.

Liu

West

Randell

, et al. A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. BMC Pregnancy Childbirth 2004; 4: 20.

142.

De Wals

Tairou

Van Allen

, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357: 135–142.

143.

Lopez-Camelo

Castilla

Orioli

IM.

Folic acid flour fortification: impact on the frequencies of 52 congenital anomaly types in three South American countries. Am J Med Genet A 2010; 152A: 2444–2458.

144.

Ismail

Eljazzar

Ganji

Intended and unintended benefits of folic acid fortification-a narrative review. Foods 2023; 12: 1612.

145.

Novaković

Geelen

Ristić- Medić

, et al. Systematic review of observational studies with dose-response meta-analysis between folate intake and status biomarkers in adults and the elderly. Ann Nutr Metab 2018; 73: 30–43.

146.

Crider

Bailey

Berry

RJ.

Folic acid food fortification-its history, effect, concerns, and future directions. Nutrients 2011; 3: 370–384.

147.

Institute of Medicine, authors. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. National Academy Press; Washington, DC, USA: 1998. Folate. pp. 196–305.

148.

Hirsch

De la Maza

Barrera

, et al. The Chilean flour folic acid fortification program reduces serum homocysteine levels and masks vitamin B-12 deficiency in elderly people. J Nutr 2002; 132: 289–291.

149.

Kancherla

Botto

Rowe

, et al. Preventing birth defects, saving lives, and promoting health equity: an urgent call to action for universal mandatory food fortification with folic acid. Lancet Glob Health 2022; 10: e1053–e1057.

150.

Sweeney

McPartlin

Scott

Folic acid fortification and public health: report on threshold doses above which unmetabolised folic acid appear in serum. BMC Public Health 2007; 7: 41.

151.

Morris

Jacques

Rosenberg

, et al. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am J Clin Nutr 2010; 91: 1733–1744.

152.

French

Grant

Weitzman

, et al. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther 2003; 74: 288–294.

153.

Grupp

Greenberg

Ray

, et al. Pediatric cancer rates after universal folic acid flour fortification in Ontario. J Clin Pharmacol 2011; 51: 60–65.

154.

Linabery

Johnson

Ross

JA.

Childhood cancer incidence trends in association with US folic acid fortification (1986–2008). Pediatrics 2012; 129: 1125–1133.

155.

Milne

Greenop

Bower

, Aus-CBT Consortiumet al. Maternal use of folic acid and other supplements and risk of childhood brain tumors. Cancer Epidemiol Biomarkers Prev 2012; 21: 1933–1941.

156.

Milne

Royle

Miller

, et al. Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring. Int J Cancer 2010; 126: 2690–2699.

157.

Metayer

Milne

Dockerty

, et al. Maternal supplementation with folic acid and other vitamins and risk of leukemia in offspring: a childhood leukemia international consortium study. Epidemiology 2014; 25: 811–822.

158.

Patel

Sobczyńska-Malefora

The adverse effects of an excessive folic acid intake. Eur J Clin Nutr 2017; 71: 159–163.

159.

Choumenkovitch

Selhub

Wilson

, et al. Folic acid intake from fortification in United States exceeds predictions. J Nutr 2002; 132: 2792–2798.

160.

Bailey

Dodd

Gahche

, et al. Total folate and folic acid intake from foods and dietary supplements in the United States: 2003–2006. Am J Clin Nutr 2010; 91: 231–237.

161.

Selhub

Rosenberg

IH.

Excessive folic acid intake and relation to adverse health outcome. Biochimie 2016; 126: 71–78.

162.

Kim

YI.

Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev 2008; 17: 2220–2225.

163.

Kim

YI.

Folic acid fortification and supplementation—good for some but not so good for others. Nutr Rev 2007; 65: 504–511.

164.

Smith

Kim

Refsum

Is folic acid good for everyone?

Am J Clin Nutr 2008; 87: 517–533.

165.

Tong

Walker

Current levels of coverage of iron and folic acid fortification are insufficient to meet the recommended intake for women of reproductive age in low- and middle-income countries. J Glob Health 2021; 11: 18002.

166.

Martín-Sabroso

Torres-Suárez

Alonso-González

, et al. Active targeted nanoformulations via folate receptors: State of the art and future perspectives. Pharmaceutics 2021; 14: 14.

167.

Bartouskova

Melichar

Mohelnikova-Duchonova

Folate receptor: a potential target in ovarian cancer. Pteridines 2015; 26: 1–12.

168.

Frigerio

Bizzoni

Jansen

, et al. Folate receptors and transporters: Biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res 2019; 38: 125.

169.

Kuplennik

Lang

Steinfeld

, et al. Folate receptor α-modified nanoparticles for targeting of the central nervous system. ACS Appl Mater Interfaces 2019; 11: 39633–39647.